After FDA’s ENDS Guidance: Why Importers and Retailers Still Face Enforcement Risk
FDA’s Guidance Is an Enforcement Policy, Not an Authorization
On May 8, 2026, FDA issued Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization (published in the Federal Register on May 12, 2026). The guidance describes how FDA intends to prioritize enforcement against certain electronic nicotine delivery system (ENDS) and oral nicotine pouch products that are on the market without premarket authorization.
The distinction that matters for everyone in the supply chain: this is enforcement policy, not authorization. A product can sit in a lower enforcement-priority tier and still be an unauthorized new tobacco product under Section 910 of the Federal Food, Drug, and Cosmetic Act. Enforcement discretion is not a marketing order, and it does not convert an illegal product into a legal one.
The timing underscored how politically charged this area has become. Within days of the guidance, Commissioner Marty Makary resigned (May 12, 2026); reporting tied his departure in part to disagreement over how aggressively FDA should treat youth-appealing flavored e-cigarettes. Kyle Diamantas is now Acting Commissioner. For industry, the lesson is that enforcement posture in this category can shift quickly with leadership and political pressure — another reason not to build a business on enforcement discretion alone.
Navigating the FDA’s enforcement landscape for nicotine pouches and ENDS products requires more than just understanding the regulations; it requires strategic risk management. I frequently work with distributors and retailers who are caught in the crosshairs of FDA enforcement against unauthorized products. Recently, I helped a client evaluate their supply chain risk, weighing the viability of manufacturing their own product line versus distributing an existing product. We analyzed the cost and timelines of PMTA testing workstreams against the immediate enforcement risks at the border and retail level. For importers and retailers, the message is clear: plausible deniability is gone, and rigorous diligence into your suppliers’ PMTA status and testing data is the only way to protect your inventory.
The Three Risk Tiers, In Plain Terms
Trade coverage has converged on a “three-tier” reading of the guidance. Here is how to think about where a SKU sits and what that means for your exposure.
| Tier | What generally falls here | What it means for you |
|---|---|---|
| Lower enforcement priority | Products covered by a PMTA that has been accepted and filed, and certain supplemental applications that have been accepted and pending for more than 180 days. FDA has tied lower priority largely to post–November 2021 reviewable applications, and for non-tobacco-flavored ENDS expects the application to include the data needed to evaluate public-health appropriateness. | Lowest near-term enforcement exposure — but still unauthorized. Tie each SKU to a specific, documented application. |
| Elevated scrutiny | Marketed products whose application posture is weak, unclear, or unsupported — e.g., a PMTA merely “submitted,” refused for acceptance, or refused to file. | Meaningful risk. Supplier assurances of “a PMTA pending” are not enough; demand documentation. |
| Highest priority | Illicit imports, misdeclared or counterfeit goods, and products with youth-appealing features (resembling candy, toys, games, or phones). | Active enforcement target across FDA and CBP. Avoid entirely. |
“Pending PMTA” Is Not a Status — Know Which One You Have
The single most common error in this space is treating “a PMTA was submitted” as if it conferred legal marketing status. It does not. The procedural posture of an application is what drives enforcement exposure, and the gradations matter commercially.
For every product you import, distribute, or shelve, you should be able to identify which rung it occupies — and back that up with the application or correspondence, not a marketing claim.
Importers Face the Earliest and Sharpest Risk
Importers are uniquely exposed because FDA and Customs and Border Protection can evaluate goods before they ever reach a shelf. FDA’s import enforcement has repeatedly targeted unauthorized ENDS, especially youth-appealing and misdeclared products. Import risk frequently arises from inaccurate product descriptions, misdeclared goods, counterfeits, inconsistent manufacturer information, and — critically — the absence of documentation tying a specific SKU to a specific pending or authorized application. A general statement that a manufacturer “has a PMTA pending” will rarely be sufficient at the border.
Retailers and Distributors: Guidance Is Not a Safe Harbor
Retailers and distributors increasingly carry real exposure of their own. FDA has taken enforcement action against retailers selling unauthorized tobacco products, including products designed to resemble everyday consumer items. A defensible program includes confirming manufacturer identity, confirming each product’s authorization or PMTA posture, checking FDA warning-letter and enforcement databases, screening packaging for youth appeal, assessing nicotine strength, reviewing import and chain-of-custody documents, and securing contractual indemnification and regulatory representations from suppliers. The goal is not zero risk — unrealistic in this category — but a documented basis for every product decision.
FDA’s Public List Is a Diligence Tool, Not a Seal of Approval
FDA has said it will maintain a public list identifying manufacturers and products it does not currently intend to prioritize for enforcement. That list is a useful diligence input. But inclusion does not mean a product is authorized, approved, endorsed, or found appropriate for the protection of public health. It reflects FDA’s current enforcement posture only — and, as the leadership change shows, that posture can move.
Practical Steps for the ENDS and Nicotine Pouch Supply Chain
Build a SKU-level regulatory file for every product, documenting authorization status, PMTA posture, supplier identity, labeling, and import history. Review packaging for youth-appeal features. Validate — don’t accept — supplier claims, demanding documentation that links the exact SKU to the relevant application. Strengthen import controls so customs descriptions, invoices, labels, and identifiers are accurate and consistent. And monitor FDA developments closely, because applications move between tiers as they are accepted, refused, denied, or authorized.
Key Takeaway
FDA’s 2026 ENDS and nicotine pouch guidance is a window into enforcement priorities, not a general safe harbor. Unauthorized products remain vulnerable — especially those with weak PMTA documentation, youth-appealing features, import irregularities, or safety concerns. For importers, retailers, and distributors, the practical message is simple: do not confuse enforcement discretion with authorization, and document every product decision.
Frequently Asked Questions
Does FDA’s enforcement guidance make my ENDS products legal to sell?
No. The guidance describes how FDA prioritizes enforcement. A “lower priority” product is still an unauthorized new tobacco product unless and until it receives marketing authorization.
Is a pending PMTA enough to keep a product on the market?
Not by itself. Lower enforcement priority generally attaches to applications that have been accepted and filed (and certain long-pending supplemental applications), not to applications that were merely submitted, refused for acceptance, or refused to file.
Can retailers be penalized, or just manufacturers?
Retailers and distributors can face enforcement directly. FDA has acted against retailers selling unauthorized products, particularly youth-appealing ones.
What should importers document?
Tie each imported SKU to a specific FDA application or authorization, and keep accurate, consistent customs descriptions, invoices, labels, and product identifiers.
This article is attorney advertising and is provided for general informational purposes only. It is not legal advice and does not create an attorney-client relationship. FDA enforcement priorities and tobacco regulation change frequently; consult qualified FDA regulatory counsel about your specific products and supply chain.
Are you in trouble with the FDA?
Don’t panic — you’ve got backup. Download 5 Tips to Help You Navigate FDA Enforcement and learn how to resolve the situation right now.